Danske Bank A S Buys Shares of 528,717 Progyny, Inc. $PGNY

Danske Bank A S purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 528,717 shares of the company’s stock, valued at approximately $15,243,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new position in Progyny in the 2nd quarter worth about $334,426,000. Wellington Management Group LLP grew its holdings in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after buying an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in Progyny in the 4th quarter valued at approximately $19,917,000. Finally, Ameriprise Financial Inc. increased its position in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of PGNY stock opened at $25.96 on Friday. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $33.06. The business’s fifty day moving average is $29.15 and its 200-day moving average is $23.50. The stock has a market cap of $1.99 billion, a PE ratio of 28.22, a price-to-earnings-growth ratio of 1.85 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period in the previous year, the business earned $0.19 earnings per share. Progyny’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities research analysts predict that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny declared that its Board of Directors has initiated a share buyback program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Canaccord Genuity Group set a $35.00 price target on Progyny in a research report on Friday, August 7th. Truist Financial raised their price target on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Leerink Partners set a $38.00 price objective on shares of Progyny in a report on Wednesday, July 22nd. Finally, BTIG Research increased their target price on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.36.

Insider Buying and Selling

In related news, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the completion of the sale, the director directly owned 9,318 shares in the company, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the transaction, the chief financial officer owned 74,688 shares in the company, valued at approximately $1,904,544. This trade represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 19,063 shares of company stock worth $489,413. 9.90% of the stock is owned by insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.